BNCERA launches Incheon plant, spurs beauty medicine market

Dignitaries cut a ribbon during BNCERA's opening ceremony for its new manufacturing plant in Namdong District, Incheon, April 21. Korea Times photo by Shim Hyun-chul

INCHEON — Aesthetic medical product developer BNCERA opened its first manufacturing plant in Korea in Incheon Tuesday, accelerating its production capacity for its key lineups of fillers, skin boosters and more.

Nestled in Namdong District of the western port city, the plant was built as a strategic base, allowing the company to respond to growing global demand. Designed and built in accordance with GMP principles, the facility supports strict quality control, process stability and product safety, while BNCERA continues the relevant GMP suitability recognition procedures, supporting BNCERA’s goal of establishing a stable supply system and strengthening quality competitiveness in line with international standards.

Key BNCERA executives including Chairman Rahmat Bozorov, co-founders Fred Bozorov, Andrew Parviz and Jaha Zoda, as well as representatives from Namdong District Office and Incheon Chamber of Commerce and Industry, participated in the ceremony. More than a hundred executives and officials from BNCERA's partner companies here also attended the event.

Park Joo-bong, chairman of the Incheon Chamber of Commerce and Industry and chairman of Daejoo-KC Group, celebrated the plant’s opening and pledged his support for its impending operations.

“By opening in Incheon, BNCERA has secured a perfect foothold for becoming a global firm,” Park said. “We’ll support BNCERA so that the Incheon-based company will expand its business worldwide and emerge as a global enterprise.”

Oh Sinan, founder and chairman of Global Business Alliance in Korea and CEO of Kervan Group, highlighted BNCERA’s success story, which began in 2018 when co-founders Andrew Parviz, Jaha Zoda and Fred Bozorov established the company.

“In Korea, there are very few successful foreign businessmen. Doing business here as a foreigner is not easy. It’s a big task. But these gentlemen, they succeeded in Korea and also got major export awards in past years. BNCERA is writing a new history in Korea,” Oh said, referring to the Export Tower Awards the company received in 2022 and 2023 from the Korean Ministry of Trade, Industry and Energy. (The ministry was renamed the Ministry of Trade, Industry and Resources last year.)

BNCERA Chairman Rahmat Bozorov, third from left, poses with the company's CEO Jaha Zoda, right, and Global Business Alliance Founder & Chairman and Kervan Group CEO Oh Sinan, second from left, outside the company's new manufacturing plant in Incheon's Namdong District, April 21. Korea Times photo by Shim Hyun-chul

BNCERA describes the plant as “more than abstract positioning” and “a physical investment that is hard to fake,” showing that the company has bet heavily on the plant, seeing it as a critical step for its future endeavors.

International distributors and physicians evaluating suppliers in Korea’s aesthetics industry consider not only product quality but also factors such as supply reliability, documentation standards, partner responsiveness and the ability to scale without compromising consistency.

In those areas, the new plant is expected to enhance BNCERA’s appeal to global clients. BNCERA said the plant was designed to support stronger process control, greater batch-to-batch consistency, enhanced scalability and improved readiness for procedural documentation and quality standards increasingly required in global regulatory environments.

"Our partners aren't just buying a product," says Zoda. "They're buying confidence in a company. That's built through documentation, consistency, and being there when it matters."

BNCERA said the plant’s opening is the “most concrete signal of its intentions.”

“Infrastructure matters in ways that marketing conversations often underestimate. Manufacturing is where trust actually lives in this industry. You can say anything in a brochure. The factory says what you mean. It’s a strategic message," Fred Bozorov said.

BNCERA currently exports to over 50 countries. It has concentrated its presence across the Commonwealth of Independent States region, Europe, Southeast Asia, the Middle East and Northern Africa, as well as the Americas. In Europe, the United Kingdom and France are the company’s strategic anchors for its market expansion across the region.

More than 200 medical professionals and global partners from 23 countries attend the symposium session of the BNCERA Aesthetic Medicine Congress 2026 in Incheon. Courtesy of BNCERA

BNCERA’s new manufacturing plant operates a 14-stage pipeline to ensure rigorous research and inspection for its hyaluronic acid aesthetic products under the Tesoro brand. Each step in the quality control process is documented, verified and fully traceable.

The process begins at the Central Research Laboratory, where all BNCERA products originate. From formula development to elasticity assessment and particle characterization, the lab provides the scientific foundation for the company’s product lineup.

Subsequent stages involve the receipt and inspection of raw materials, followed by precise weighing for production. The materials then go through dissolution crosslinking, dialysis purification, milling gel homogenization, lidocaine incorporation blending, syringe filling and sterilization. After three rounds of testing, the products go through automated particle inspection, assembly, labeling and packaging before being stored and delivered to clients.

BNCERA retains a unique technology called H.E.R.S. Cross-linking. H.E.R.S. stands for “high quality, elasticity, refined, systematic control,” and represents a cross-linking philosophy designed to shape performance, consistency and physician handling. Yang Jin-hyo, head of the company’s R&D team, said the technology is the company’s “formulation approach to elasticity, consistency and controlled quality.”

Hwang Yoo-jin, head of the company’s production team, added during the opening ceremony that precision milling and classification support more uniform particle profile for smoother injection, better control and more predictable in-tissue behavior. Dual-layer particle verification, in-house produced water for injection and validated clean room for controlled conditions also contribute to BNCERA's quality that is “verified, not assumed.”